ResultsIQ

ResultsIQ › Latest results › Lotus Eye Hospital and Institute Limited

Lotus Eye Hospital and Institute Limited Q2 FY27 results press release summary

NSE: LOTUSEYE · BSE: 532998

Results press release of 12 Nov 2026, summarised by AI from the filing.

Lotus Eye Hospital Q2 FY27 revenue from operations ₹17.72 cr, up approximately 36%, with net profit ₹43.95 lakh.

Key takeaways

  1. Q2 revenue Revenue from operations ₹17.72 cr (Q2 FY26: ₹13.04 cr, growth of approximately 36%).
  2. H1 net profit H1 net profit ₹1.05 cr (H1 FY26: ₹66.06 lakh, increase of approximately 59%).
  3. H1 revenue H1 revenue from operations ₹34.78 cr (H1 FY26: ₹26.56 cr, growth of approximately 31%).
  4. Profitability The company attributes the performance to continued revenue growth and improving profitability.

Original filing on BSE

Lotus Eye Hospital and Institute Limited Q2 FY27 results

As filed: Revenue ₹17.7 cr, EBITDA ₹2.6 cr, PAT ₹0.4 cr, EBITDA margin 14.4%.

Not scored. Too small to score: quarter revenue ₹17.7 cr is below the ₹20.0 cr minimum. On a base this small, percentage changes say little.

Earlier results and the share price after them

  • Q1 FY27: Revenue ₹17.1 cr, EBITDA ₹3.0 cr, PAT ₹0.6 cr, EBITDA margin 17.3%. Not scored. Too small to score: quarter revenue ₹17.1 cr is below the ₹20.0 cr minimum. On a base this small, percentage changes say little. Share price after the results: −4.0% in 30 days (Nifty 500: −3.3%).
  • Q4 FY26: Revenue ₹13.6 cr, EBITDA ₹0.5 cr, PAT −₹0.3 cr, EBITDA margin 3.5%. Not scored. Too small to score: quarter revenue ₹13.6 cr is below the ₹20.0 cr minimum. On a base this small, percentage changes say little. Share price after the results: +14.3% in 30 days (Nifty 500: +0.9%).
  • Q3 FY26: Revenue ₹13.6 cr, EBITDA ₹0.7 cr, PAT −₹0.3 cr, EBITDA margin 4.8%. Not scored. Too small to score: quarter revenue ₹13.6 cr is below the ₹20.0 cr minimum. On a base this small, percentage changes say little. Share price after the results: −15.7% in 30 days (Nifty 500: −10.1%).
  • Q2 FY26: Revenue ₹13.0 cr, EBITDA ₹1.0 cr, PAT ₹0.0 cr, EBITDA margin 7.7%. Not scored. Too small to score: quarter revenue ₹13.0 cr is below the ₹20.0 cr minimum. On a base this small, percentage changes say little. Share price after the results: +9.9% in 30 days (Nifty 500: −0.5%).
  • Q1 FY26: Revenue ₹14.0 cr, EBITDA ₹2.0 cr, PAT ₹1.0 cr, EBITDA margin 14.3%. Not scored. Too small to score: quarter revenue ₹14.0 cr is below the ₹20.0 cr minimum. On a base this small, percentage changes say little. Share price after the results: +63.9% in 30 days (Nifty 500: +2.4%).
  • Q4 FY25: Revenue ₹12.0 cr, EBITDA −₹1.0 cr, PAT ₹0.0 cr, EBITDA margin -8.3%. Not scored. Too small to score: quarter revenue ₹12.0 cr is below the ₹20.0 cr minimum. On a base this small, percentage changes say little. Share price after the results: −1.0% in 29 days (Nifty 500: +3.3%).
  • Q3 FY25: Revenue ₹12.0 cr, EBITDA ₹1.0 cr, PAT ₹0.0 cr, EBITDA margin 8.3%. Not scored. Too small to score: quarter revenue ₹12.0 cr is below the ₹20.0 cr minimum. On a base this small, percentage changes say little.

Past price moves after results do not indicate future moves. Not a recommendation.

Lotus Eye Hospital and Institute Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.